Characteristics of patients included in the present study#
| Total group | CF | Non-CF | |
| Subjects | 92 | 26 | 66 |
| Age at SSLTx yrs | 43.5 (27.5–53) | 26 (21.5–31.5) | 48.5 (43–54) |
| Sex M/F | 52/40 | 14/12 | 38/28 |
| Pre-LTx diagnosis | |||
| α1-Antitrypsin deficiency | 7 | 7 | |
| Bronchiectasis | 4 | 4 | |
| CF | 26 | 26 | |
| Emphysema (COPD) | 31 | 31 | |
| Pulmonary arterial hypertension | 6 | 6 | |
| Pulmonary fibrosis | 13 | 13 | |
| BOS | 2 | 2 | |
| Other | 3 | 3 | |
| Pre-LTx colonisation with Pseudomonads | 33/92 (35.8) | 25/26 (96.1) | 8/66 (12.1) |
| Alcaligenes | 2 | 2 | |
| Burkholderia | 1 | 1 | |
| Pseudomonas | 26 | 21 | 5 |
| Stenotrophomonas | 4 | 1 | 3 |
| Post-LTx colonisation with Pseudomonads | 39/92 (42.4) | 16/26 (61.5) | 23/66 (34.8) |
| Alcaligenes | 1 | 1 | |
| Burkholderia | 1 | 1 | |
| Pseudomonas | 35 | 14 | 21 |
| Stenotrophomonas | 2 | 2 | |
| Time of follow-up days | 1213 (718–1736) | 1126 (779.5–2033) | 1255 (671.5–1686) |
| Time to colonisation with Pseudomonads days | 131 (79–421) | 121 (46–445) | 179 (88–396) |
| Interval colonisation to BOS stage ≥1 days | 196.5 (79–672.5) | 181.5 (122–218.5) | 509 (37–784.5) |
| Time to BOS stage≥1 days | |||
| All patients | 505 (326–1192) | 426 (272–862) | 559 (337–1231) |
| Noncolonised patients | 559 (326–1466) | 559 (326–1466) | |
| Colonised patients | 479 (323–924) | 426 (272–862) | 581 (372–1002) |
| Prevalence of BOS ≥1 | |||
| All patients | 23/92 (25) | 8/26 (30.7) | 15/66 (22.7) |
| Noncolonised patients | 7/53 (13.2) | 0/10 (0) | 7/43 (16.2) |
| Colonised patients | 16/39 (41.0) | 8/16 (50) | 8/23 (34.8) |
| Time to inhaled colistin treatment days | 9.5 (2–15.5) | 9 (2–12.5) | 200 (-) |
| Duration of colistin treatment days | 80 (64.5–134.5) | 76 (58.5–93) | 239 (-) |
| Prevalence of colistin treatment | |||
| All patients | 20/92 (21.7) | 17/26 (65.4) | 3/66 (4.5) |
| Noncolonised patients | 6/53 (11.3) | 6/10 (60) | 0/43 (0) |
| Colonised patients | 14/39 (35.9) | 11/16 (68.8) | 3/23 (13) |
| Time to azithromycin treatment days | 399 (131–761) | 493 (378–597.5) | 240.5 (105–908) |
| Prevalence of azithromycin treatment | |||
| All patients | 35/92 (38) | 9/26 (34.6) | 26/66 (39.4) |
| Noncolonised patients | 13/53 (24.5) | 0/10 (0) | 13/43 (30.2) |
| Colonised patients | 22/39 (56.4) | 9/16 (56.3) | 13/23 (56.5) |
| Mortality | |||
| All patients | 9/92 (9.8) | 2/26 (7.7) | 7/66 (10.6) |
| Noncolonised patients | 3/53 (5.7) | 0/10 (0) | 3/43 (6.9) |
| Colonised patients | 6/39 (15.4) | 2/16 (12.5) | 4/23 (17.4) |
Data are presented as n, median (range) or n/n (%). CF: cystic fibrosis; (SS)LTx: (double) lung transplant; M: male; F: female; COPD: chronic obstructive pulmonary disease; BOS: bronchiolitis obliterans syndrome. #: patient characteristics are given for all included SSLTx recipients (n = 92), composed of CF and non-CF SSLTx recipients.